CClinicalTrials.gg
TerminatedNCT05138419PACEDUpdated Jan 7, 2026Results posted

A Pragmatic Approach to CKD Patient Education

An interventional study of CKD "What You Need To Know" Workbook System and CKD Action Plan in Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 and Chronic Kidney Disease Stage 5, sponsored by University of Arkansas. Terminated at 1 site in United States. Open to participants aged 18 Years to 105 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by University of Arkansas · Not applicable, Interventional, and Prevention

Why this study was terminated
IRB CR Expired
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 105 Years
Sex
All
01

Study summary

Over 350,000 adult Arkansans have chronic kidney disease (CKD) and 9 out of 10 (312,000) of these Arkansans are unaware of having it. A "Know Your Kidney Number" (eGFR) poster (KYKN) campaign is being launched statewide to increase CKD awareness and detection. As awareness increases, the demand for patient education will increase. Educating patients has proven to be effective in delaying CKD progression and establishing optimal renal replacement therapy (RRT) when needed. CKD patient education has historically been provided by nephrology clinicians. Yet most patients are not referred to nephrology until the patient is nearing the need for RRT. Novel pragmatic approaches to reaching and educating patients earlier in their disease state and partnering with a broader pool of clinicians that can provide the education is needed. Most problems related to CKD start when kidney function is \~45 %, earlier education can empower patients to make changes to protect their kidney function earlier and plan for RRT.

University of Arkansas for Medical Sciences (UAMS) developed and copyrighted the "CKD: What You Need to Know" patient education system. Research showed almost 90% of the attendees could choose a modality after either tele-education (TE) or face to face (FTF) education. Home modality choices doubled. Patients were able to make informed choices regardless of the modality of education. Of those starting RRT 47% started on a home modality or received a transplant. This compares to 10% nationally. Both transplant and home dialysis have better outcomes and are less costly compared to in-center hemodialysis.

Harp's Pharmacy has a successful medication therapy management (MTM) program where pharmacists are provided time for patient-centered activities for patients with diabetes (DM), hypertension (HTN), the 2 leading causes for CKD, and heart failure (HF), the leading cause of death in CKD. Thirty six percent of patients with DM will develop CKD and hypertension can be both a cause and an effect of CKD. In this project Harp's Pharmacy will use the MTM infrastructure to add CKD to the program in select pharmacies in the delta. The CKD tools build on and support actions that improve the underlying conditions that are already being addressed. The "CKD: What You Need to Know" tools will be used with patients with known CKD or 2 of the 3 conditions covered by MTM and randomized into 1 of 2 education arms that offer various levels of support or a control arm.

Read the detailed description

Using non-nephrology clinicians to expand access to CKD education earlier in the patient's disease progress is essential. This project will inform how various levels of support provided by pharmacists and staff using nephrology developed tools in self-study models can 1) effect patient's ability to select the End Stage Renal Disease (ESRD) modality (Incenter hemodialysis, home hemodialysis, peritoneal dialysis, no dialysis or do not have enough information to make a choice) to use if or when dialysis is needed 2) identify patient's interest in obtaining a renal transplant and, if so, has a possible donor been identified 3) identify actions they are willing to take to protect their current kidney function using a CKD Action Plan that contains 1 knowledge goal and 10 performance goals based on international guidelines 4) allow comparisons of support time and outcomes for each of the 3 groups. Empowering patients to be proactive partners in their health care, through education and accountability, by choosing both the RRT and performance goals to protect the patient's kidneys is key to improving outcomes. Demonstrating that non-nephrology clinicians can effectively educate and support these patients will provide models that other clinicians can use.

Minorities, especially in rural areas, are less likely to receive most kinds of care including evidence-based practices, home dialysis or transplantation. Developing patient-centered approaches to care such as this project can reduce disparities.

One-on-one outreach to educate, motivate and seek the patient's feedback can strengthen commitment and adherence to medical regimens. Learning what to expect can promote self-management behaviors.

The Arkansas Department of Health (ADH) Southeast (SE) region covers most of the Delta and was selected because the SE region had the poorest outcomes for patients starting RRT. In 2017, new patients were predominately black (61%), less than half had seen a nephrologist prior to starting RRT, only 1.3% had seen a dietitian, most (92.3%) started hemodialysis using a catheter and 2.1% started on home peritoneal dialysis. Only 2.1% had no insurance. This data can be tracked annually to track impact.

The tools being used were developed by a multidisciplinary team of nephrology experts which are limited in the delta. Courses including train the trainer classes for pharmacies and 10 points of Care for CKD for clinicians will be conducted. Collaboration with local providers can both educate and promote community engagement.

Harp pharmacists expressed randomization concerns. Harp's Pharmacy reported that many of the MTM subjects have multiple family members or friends enrolled in the study. This could confound randomization into various arms since these subjects are highly likely to compare and contrast the details of the patient's intervention. The research team decided that a cluster randomization schedule would be utilized with each cluster self-selecting a leader that would be enrolled in the study and be responsible for the education of the other cluster members. All cluster members will undergo the same testing.

02

Conditions studied

  • Chronic Kidney Disease stage3
  • Chronic Kidney Disease stage4
  • Chronic Kidney Disease Stage 5
  • Patient Engagement

Keywords

  • Patient Education
  • Patient Engagement
  • Chronic Kidney Disease
03

In context

Renal Insufficiency, Chronic

3,144 studies on the registry are indexed under Renal Insufficiency, Chronic; 704 are open to participants now.

This study's enrollment of 1 is below the median of 74 across 2,176 interventional studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

University of Arkansas is the lead sponsor of 391 studies on the registry; 39 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 34 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 105 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults (any gender)>18 years old
  • Enrolled in Harp's MTM program
  • Has Known CKD or 2 of the 3 conditions covered in MTM (DM, HTN and Heart Failure)
  • Not on dialysis

Exclusion criteria

Exclusion Criteria:

  • unable to read or speak English
  • history of significant cognitive dysfunction unless qualified caregiver is the one being educated
  • not personally independent or without any social support
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Active comparator
    Case Management Model (CMM)

    CMM includes 3 visits of pharmacist initiated discussion of workbook content (including AP \[action plan\] and CKD web-based sites) and AP reinforcement. Pre-testing is done on Visit 1 (V1) and Post testing and program evaluation on V3. Subjects are asked to read 1 chapter a week, write down questions and take tests at the end of chapters. On V1 pharmacist introduces the Workbook System highlighting chapters 1-4 and assist with AP goal selection. On V2, the pharmacist answers questions, provides chapter 4-8 highlights and reviews AP goal progress and food label exercise. On V3, pharmacist answers questions, expands on workbook content and reviews AP goals progress and program evaluation including modality and transplant questions from pre/posttests, identification and ranking of peer cluster leader teaching style and effectiveness, identification of AP goals selected and ranking of helpfulness is completed. Pharmacists track time spent at each visit to compare cost and outcomes.

    Other: CKD "What You Need To Know" Workbook System · Other: CKD Action Plan · Other: CKD Web-based Resource List · Other: Food Label reading exercise

  • Active comparator
    Self Study (SS)

    SS includes 2 visits. Subjects receive the workbook, paper copies of AP and food label exercise. Pre-testing will be done on V1 and Post testing on V2, eight weeks later. Subjects will be asked to read 1 chapter a week for the next 8 weeks. The pharmacist will provide a brief introduction of the workbook (5-10 minutes) and the AP. Only subject initiated questions will be answered. On V2, the pharmacist will answer subject initiated questions and ask about progress in the AP goal attainment and the program evaluation will be completed, as described in arm 1.Pharmacists track time spent at each visit to compare cost and outcomes.

    Other: CKD "What You Need To Know" Workbook System · Other: CKD Action Plan · Other: CKD Web-based Resource List · Other: Food Label reading exercise

  • Sham comparator
    Control (Ctrl)

    Ctrl includes 2 visits. Subjects receive a list of web-based CKD sites, a food label exercise and a copy of the AP with no additional intervention, other than answering subject initiated questions, on V1. Pre-testing will be done on V1 and Post testing on V2 and program evaluation will be done eight weeks later. On V2, the pharmacist will ask about AP goals and answer subject initiated questions. Pharmacists track time spent at each visit to compare cost and outcomes.

    Other: CKD Action Plan · Other: CKD Web-based Resource List · Other: Food Label reading exercise

Interventions

  • OtherCKD "What You Need To Know" Workbook System

    139 page Workbook including CKD Action Plan, Web-Based Resources, Interactive CKD Patient education material

  • OtherCKD Action Plan

    Goals based on international guidelines that can protect kidney function (1 knowledge and 10 action goals) Patient education material used separately for control arm.

  • OtherCKD Web-based Resource List

    CKD Patient education material used separately for control arm

  • OtherFood Label reading exercise

    CKD Patient education material used separately in all arms.

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Can Choose a Dialysis Modality by the End of the Study.

    This primary study aim is to increase the subject's ability to select a dialysis modality. Descriptive statistics will be used to examine the trend in the subjects' ability to choose or not choose a dialysis modality. Descriptive statistics will be used to examine the trend of patients answers based on comparisons of responses on pre and post tests and evaluation form with the options of Incenter Hemodialysis (ICH), Home Hemodialysis (HH), Peritoneal Dialysis (PD), No Dialysis, don't have enough information to make a to make a decision.

    Time frame: up to 4 months

  2. Number of Subjects That Choose a Form of Home Dialysis (Home Hemodialysis or Peritoneal Dialysis) by the End of the Study.

    This aim is to identify the impact interventions have on the subject's choice of modality (home dialysis versus in-center hemodialysis). Descriptive statistics will be used to examine the trend of patients answers based on comparisons of responses on pre and post tests and evaluation form with the options of Incenter Hemodialysis (ICH), Home Hemodialysis (HH), Peritoneal Dialysis (PD).

    Time frame: up to 4 months

  3. Number of Subjects Interested in Kidney Transplant (Pre-test)

    Descriptive statistics will be used to examine the trend in the subjects' level of interest in kidney transplant based on pre-test, post-test and evaluation form answers.

    Time frame: before implementation of the intervention, average of 1 week

  4. Number of Subjects Interested in Kidney Transplant (Post-test)

    Descriptive statistics will be used to examine the trend in the subjects' level of interest in kidney transplant based on post-test evaluation form answers.

    Time frame: after the intervention, up to 4 months

  5. Number of Subjects With a Possible Donor Identified (Pre-test)

    Descriptive statistics will be used to examine the trend in the subjects' selection of a possible donor based on pre-test evaluation form answers.

    Time frame: before implementation of the intervention, average of 1 week

  6. Number of Subjects With a Possible Donor Identified (Post-test)

    Descriptive statistics will be used to examine the trend in the subjects' selection of a possible donor based on post-test evaluation form answers.

    Time frame: after the intervention, up to 4 months

Secondary outcomes

  1. Intra Cluster Analysis to Evaluate Effectiveness of Each Teaching Style Used by Peer Educators

    Clusters of more than 1 subject will undergo intra cluster analysis per each arm using data from the evaluation form to determine effectiveness of each teaching style used. Examples: Comparisons of self study versus cluster group participation of Workbook content and Handouts materials (Workbook, Chapter Post Tests, Chapter Frequently Asked Questions, Web-sites accessed, Food label exercise outcomes. Number of cluster meetings, Were modality choices discussed, How helpful was their experience (1-5 scale). Open comment section for subjects to expand on their experience, what was especially helpful and what could be improved.

    Time frame: Up to 4 months

  2. Patient Engagement (Percent of Applicable Action Plan (AP) Goals Selected)

    Patient Engagement will be measured by the percent of applicable AP goals selected The AP has 10 performance goals that are specific, actionable and realistic addressing these areas 1) Diabetes: Goal Hemoglobin A1C (A1C) 2) B/P Goal 3) Exercise Goal 4) Medications to Avoid, ensure taken, system to reorder 5) Stop Smoking 6-7) Kidney Friendly Diet: salt/water/edema, phosphorus/ protein 8) Monitor System for glucose checks, home blood pressure, weight, diet diary 9) Weight Management 10) Anemia: Goal hemoglobin. When AP is initiated goals already met or are don't apply to subject will be identified. Subject can then select goals to start.

    Time frame: up to 4 months

  3. Patient Engagement (Percent of Visits Where a Patient-initiated CKD Discussion Takes Place)

    Patient Engagement will be measured by the percent of visits where a patient-initiated CKD discussion occurred

    Time frame: up to 4 months

  4. Patient Engagement (Percent of Goals Met)

    Patient Engagement will be measured by the percent of goals met (self-reported or provider-confirmed). Goal completion will be determined from evaluation form, AP form, or study flow sheet.

    Time frame: up to 4 months

  5. Amount of Time Spent by Pharmacist and Staff Per Subject

    Pharmacist and staff will note the time spent on CKD-related issues at each visit on the study flow sheet.

    Time frame: up to 4 months

07

Results

Posted Jan 7, 2026
Limitations and caveats
Early termination due to the pharmacies staffing problems. Major barriers were pharmacist time and low literacy levels of many of their patients. Funding was too low but if data showed positive outcomes for patients getting early CKD education in local pharmacies, Medicare could expand CKD education coverage to include pharmacists (currently limited to. Nephrology clinicians).

Participant flow

Participant flow — Overall Study
MilestoneCase Management Model (CMM)Self Study (SS)Control (Ctrl)
Started001
Completed000
Not completed001
Withdrew: Study terminated before participant completed.001

Outcome measures

PrimaryNumber of Subjects Who Can Choose a Dialysis Modality by the End of the Study.

This primary study aim is to increase the subject's ability to select a dialysis modality. Descriptive statistics will be used to examine the trend in the subjects' ability to choose or not choose a dialysis modality. Descriptive statistics will be used to examine the trend of patients answers based on comparisons of responses on pre and post tests and evaluation form with the options of Incenter Hemodialysis (ICH), Home Hemodialysis (HH), Peritoneal Dialysis (PD), No Dialysis, don't have enough information to make a to make a decision.

Time frame:
up to 4 months

No measurements were reported for this outcome.

PrimaryNumber of Subjects That Choose a Form of Home Dialysis (Home Hemodialysis or Peritoneal Dialysis) by the End of the Study.

This aim is to identify the impact interventions have on the subject's choice of modality (home dialysis versus in-center hemodialysis). Descriptive statistics will be used to examine the trend of patients answers based on comparisons of responses on pre and post tests and evaluation form with the options of Incenter Hemodialysis (ICH), Home Hemodialysis (HH), Peritoneal Dialysis (PD).

Time frame:
up to 4 months

No measurements were reported for this outcome.

PrimaryNumber of Subjects Interested in Kidney Transplant (Pre-test)

Descriptive statistics will be used to examine the trend in the subjects' level of interest in kidney transplant based on pre-test, post-test and evaluation form answers.

Time frame:
before implementation of the intervention, average of 1 week

No measurements were reported for this outcome.

PrimaryNumber of Subjects Interested in Kidney Transplant (Post-test)

Descriptive statistics will be used to examine the trend in the subjects' level of interest in kidney transplant based on post-test evaluation form answers.

Time frame:
after the intervention, up to 4 months

No measurements were reported for this outcome.

PrimaryNumber of Subjects With a Possible Donor Identified (Pre-test)

Descriptive statistics will be used to examine the trend in the subjects' selection of a possible donor based on pre-test evaluation form answers.

Time frame:
before implementation of the intervention, average of 1 week

No measurements were reported for this outcome.

PrimaryNumber of Subjects With a Possible Donor Identified (Post-test)

Descriptive statistics will be used to examine the trend in the subjects' selection of a possible donor based on post-test evaluation form answers.

Time frame:
after the intervention, up to 4 months

No measurements were reported for this outcome.

SecondaryIntra Cluster Analysis to Evaluate Effectiveness of Each Teaching Style Used by Peer Educators

Clusters of more than 1 subject will undergo intra cluster analysis per each arm using data from the evaluation form to determine effectiveness of each teaching style used. Examples: Comparisons of self study versus cluster group participation of Workbook content and Handouts materials (Workbook, Chapter Post Tests, Chapter Frequently Asked Questions, Web-sites accessed, Food label exercise outcomes. Number of cluster meetings, Were modality choices discussed, How helpful was their experience (1-5 scale). Open comment section for subjects to expand on their experience, what was especially helpful and what could be improved.

Time frame:
Up to 4 months

No measurements were reported for this outcome.

SecondaryPatient Engagement (Percent of Applicable Action Plan (AP) Goals Selected)

Patient Engagement will be measured by the percent of applicable AP goals selected The AP has 10 performance goals that are specific, actionable and realistic addressing these areas 1) Diabetes: Goal Hemoglobin A1C (A1C) 2) B/P Goal 3) Exercise Goal 4) Medications to Avoid, ensure taken, system to reorder 5) Stop Smoking 6-7) Kidney Friendly Diet: salt/water/edema, phosphorus/ protein 8) Monitor System for glucose checks, home blood pressure, weight, diet diary 9) Weight Management 10) Anemia: Goal hemoglobin. When AP is initiated goals already met or are don't apply to subject will be identified. Subject can then select goals to start.

Time frame:
up to 4 months

No measurements were reported for this outcome.

SecondaryPatient Engagement (Percent of Visits Where a Patient-initiated CKD Discussion Takes Place)

Patient Engagement will be measured by the percent of visits where a patient-initiated CKD discussion occurred

Time frame:
up to 4 months

No measurements were reported for this outcome.

SecondaryPatient Engagement (Percent of Goals Met)

Patient Engagement will be measured by the percent of goals met (self-reported or provider-confirmed). Goal completion will be determined from evaluation form, AP form, or study flow sheet.

Time frame:
up to 4 months

No measurements were reported for this outcome.

SecondaryAmount of Time Spent by Pharmacist and Staff Per Subject

Pharmacist and staff will note the time spent on CKD-related issues at each visit on the study flow sheet.

Time frame:
up to 4 months

No measurements were reported for this outcome.

Adverse events

Collected over 2 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Case Management Model (CMM)———
Self Study (SS)———
Control (Ctrl)0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

Study terminated before participate completed

Age, Categorical
Age, Categorical(Participants)Case Management Model (CMM)Self Study (SS)Control (Ctrl)Total
<=18 years——00
Between 18 and 65 years——11
>=65 years——00
Sex: Female, Male
Sex: Female, Male(Participants)Case Management Model (CMM)Self Study (SS)Control (Ctrl)Total
Female0011
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Case Management Model (CMM)Self Study (SS)Control (Ctrl)Total
Hispanic or Latino0011
Not Hispanic or Latino——00
Unknown or Not Reported——00
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Case Management Model (CMM)Self Study (SS)Control (Ctrl)Total
American Indian or Alaska Native——00
Asian——00
Native Hawaiian or Other Pacific Islander——00
Black or African American——00
White——11
More than one race——00
Unknown or Not Reported——00
08

Study locations

1 site
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
09

References and documents

Publications

  • Easom AM, Shukla AM, Rotaru D, Ounpraseuth S, Shah SV, Arthur JM, Singh M. Home run-results of a chronic kidney disease Telemedicine Patient Education Study. Clin Kidney J. 2019 Aug 22;13(5):867-872. doi: 10.1093/ckj/sfz096. eCollection 2020 Oct. PubMed 33123362 ↗
  • Shukla AM, Easom A, Singh M, Pandey R, Rotaru D, Wen X, Shah SV. Effects of a Comprehensive Predialysis Education Program on the Home Dialysis Therapies: A Retrospective Cohort Study. Perit Dial Int. 2017 Sep-Oct;37(5):542-547. doi: 10.3747/pdi.2016.00270. Epub 2017 May 25. PubMed 28546368 ↗
  • Neil N, Guest S, Wong L, Inglese G, Bhattacharyya SK, Gehr T, Walker DR, Golper T. The financial implications for Medicare of greater use of peritoneal dialysis. Clin Ther. 2009 Apr;31(4):880-8. doi: 10.1016/j.clinthera.2009.04.004. PubMed 19446160 ↗
  • Waterman AD, Browne T, Waterman BM, Gladstone EH, Hostetter T. Attitudes and behaviors of African Americans regarding early detection of kidney disease. Am J Kidney Dis. 2008 Apr;51(4):554-62. doi: 10.1053/j.ajkd.2007.12.020. Epub 2008 Mar 6. PubMed 18371531 ↗
  • Szczech LA, Stewart RC, Su HL, DeLoskey RJ, Astor BC, Fox CH, McCullough PA, Vassalotti JA. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One. 2014 Nov 26;9(11):e110535. doi: 10.1371/journal.pone.0110535. eCollection 2014. PubMed 25427285 ↗
  • Weis L, Metzger M, Haymann JP, Thervet E, Flamant M, Vrtovsnik F, Gauci C, Houillier P, Froissart M, Letavernier E, Stengel B, Boffa JJ; NephroTest Study Group. Renal function can improve at any stage of chronic kidney disease. PLoS One. 2013 Dec 13;8(12):e81835. doi: 10.1371/journal.pone.0081835. eCollection 2013. PubMed 24349134 ↗

Study documents

  • Protocol and statistical analysis plan · Dec 14, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05138419
Lead sponsor
University of Arkansas
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Feb 13, 2023
Primary completion
Oct 23, 2024
Completion
Oct 23, 2024
Results posted
Jan 7, 2026
Last update
Jan 7, 2026

Study contacts

Manisha Singh, MD
principal investigator · UAMS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion